CSTL Stock Overview
A molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus, uveal melanoma, and mental health conditions. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Castle Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$27.53 |
| 52 Week High | US$35.84 |
| 52 Week Low | US$16.97 |
| Beta | 0.89 |
| 1 Month Change | -7.65% |
| 3 Month Change | -8.14% |
| 1 Year Change | 27.28% |
| 3 Year Change | -35.35% |
| 5 Year Change | -19.01% |
| Change since IPO | 28.64% |
Recent News & Updates
Castle Biosciences (NASDAQ:CSTL) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Dec 12
Are Investors Undervaluing Castle Biosciences, Inc. (NASDAQ:CSTL) By 49%?
Oct 15Recent updates
Castle Biosciences (NASDAQ:CSTL) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Dec 12Are Investors Undervaluing Castle Biosciences, Inc. (NASDAQ:CSTL) By 49%?
Oct 15Castle Biosciences: Inflection Into Profitability
Aug 16Upgrade: Analysts Just Made A Meaningful Increase To Their Castle Biosciences, Inc. (NASDAQ:CSTL) Forecasts
Aug 11Castle Biosciences, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates
Aug 08Castle Biosciences, Inc.'s (NASDAQ:CSTL) 28% Share Price Surge Not Quite Adding Up
Aug 04Is Castle Biosciences (NASDAQ:CSTL) A Risky Investment?
Jul 12Castle Biosciences, Inc.'s (NASDAQ:CSTL) P/S Is On The Mark
Apr 30Investors Appear Satisfied With Castle Biosciences, Inc.'s (NASDAQ:CSTL) Prospects
Jan 27Castle Biosciences (NASDAQ:CSTL) Is In A Good Position To Deliver On Growth Plans
Oct 31Earnings Working Against Castle Biosciences, Inc.'s (NASDAQ:CSTL) Share Price Following 36% Dive
Jun 13Analysts Just Published A Bright New Outlook For Castle Biosciences, Inc.'s (NASDAQ:CSTL)
Aug 14Shareholder Returns
| CSTL | US Healthcare | US Market | |
|---|---|---|---|
| 7D | -4.6% | -4.1% | -2.4% |
| 1Y | 27.3% | -10.2% | 23.4% |
Return vs Industry: CSTL exceeded the US Healthcare industry which returned -10.2% over the past year.
Return vs Market: CSTL exceeded the US Market which returned 23.3% over the past year.
Price Volatility
| CSTL volatility | |
|---|---|
| CSTL Average Weekly Movement | 7.4% |
| Healthcare Industry Average Movement | 7.6% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CSTL has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: CSTL's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 710 | Derek Maetzold | castlebiosciences.com |
Castle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett’s esophagus. In addition, the company provides DecisionDx-UM test, a proprietary risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide drug treatment for major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder.
Castle Biosciences, Inc. Fundamentals Summary
| CSTL fundamental statistics | |
|---|---|
| Market cap | US$771.04m |
| Earnings (TTM) | US$6.08m |
| Revenue (TTM) | US$311.88m |
126.9x
P/E Ratio2.5x
P/S RatioIs CSTL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CSTL income statement (TTM) | |
|---|---|
| Revenue | US$311.88m |
| Cost of Revenue | US$56.45m |
| Gross Profit | US$255.43m |
| Other Expenses | US$249.36m |
| Earnings | US$6.08m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.22 |
| Gross Margin | 81.90% |
| Net Profit Margin | 1.95% |
| Debt/Equity Ratio | 2.3% |
How did CSTL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 06:12 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Castle Biosciences, Inc. is covered by 9 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Catherine Ramsey Schulte | Baird |
| Mark Massaro | BTIG |
| Kyle Mikson | Canaccord Genuity |